Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia

Area of Science:

• Oncology
• Pharmacology
• Cardiology

Background:

• Cancer cachexia causes over 20% of cancer-related deaths, worsening patient quality of life through symptoms like depression and anorexia.
• Cardiac atrophy and dysfunction are observed in cancer cachexia rodent models, contributing to mortality.
• The antidepressant and anxiolytic drug tandospirone's effects on cancer cachexia require characterization.

Purpose of the Study:

• To investigate the efficacy of tandospirone in mitigating wasting, improving cardiac function, and enhancing survival in experimental cancer cachexia.
• To assess the impact of tandospirone on body composition, physical activity, and food intake in tumor-bearing rats.

Main Methods:

• Utilized the Yoshida hepatoma rat model of cancer cachexia.
• Administered varying doses of tandospirone (1mg/kg/d LD, 10mg/kg/d HD) or placebo to tumor-bearing rats.
• Assessed body weight, composition (NMR), cardiac function (echocardiography), activity, food intake, plasma noradrenaline and cortisol, and muscle caspase activity.

Main Results:

• High-dose tandospirone (10mg/kg/d) significantly reduced body weight loss, primarily by preserving muscle mass.
• HD tandospirone increased locomotor activity and food intake, improved cardiac function and weight, and reduced plasma noradrenaline and cortisol levels.
• HD tandospirone significantly improved survival rates in tumor-bearing rats compared to placebo.

Conclusions:

• Tandospirone demonstrates significant beneficial effects in a rat model of cancer cachexia.
• The drug's ability to preserve muscle mass, improve cardiac function, and enhance survival warrants further investigation.
• Tandospirone shows promise as a potential therapeutic agent for cancer cachexia syndrome.